In response to inquiries from providers about coverage of tumor treating fields therapy (TTF), Harvard Pilgrim has developed a new medical policy for this treatment. TTF therapy uses alternating electric fields to inhibit cell proliferation and leads to programmed cell death in the treatment of glioblastoma, a cancer that forms from star-shaped cells in the brain called astrocytes.
Effective for dates of service beginning October 1, 2016, Harvard Pilgrim provides coverage for medically necessary TTF in the following cases:
- For the treatment of histologically confirmed glioblastoma (GBM) in members 18 years of age or older
- When used with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed, supra-tentorial GBM following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy
- For the treatment of recurrent GBM when used as a monotherapy after surgical and radiation options have been exhausted
For more complete information, please refer to the Tumor Treatment Field Medical Policy.